China Resources Jiangzhong: The company's revenue in 2025 is expected to decline year-over-year, but profitability is improving mainly due to two factors.

Securities Daily Network March 24 News, China Resources Jiangzhong stated during a Q&A session with researchers that in 2025, due to overall industry pressure, changes in end-user demand, and adjustments in channel structure, the company’s revenue is expected to decline year-on-year. However, profitability is improving, mainly due to two factors: first, the company is continuously promoting refined management and cost control, steadily improving operational efficiency, and continuously optimizing the cost structure; second, the optimization of the company’s product structure, with core products such as digestive tablets and Beifeida showing steady growth and an increasing revenue share, which drives overall profitability improvement. Regarding dividends, the company adheres to the concept of co-prosperity between investors and listed companies, implementing cash dividends twice a year during the 14th Five-Year Plan period, with the cash dividend ratio ranking among the top in the traditional Chinese medicine industry. In the future, the company will maintain a relatively stable dividend amount and frequency while comprehensively considering factors such as capital expenditures and business development needs, sharing the results of its development with shareholders.

(Editor: Ren Shibi)